TD Cowen Issues Positive Forecast for CeriBell (NASDAQ:CBLL) Stock Price

CeriBell (NASDAQ:CBLL) had its price target upped by TD Cowen from $31.00 to $36.00 in a research note issued to investors on Monday,Benzinga reports. TD Cowen currently has a buy rating on the stock.

A number of other equities analysts have also commented on CBLL. Bank of America began coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $32.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price target for the company. Canaccord Genuity Group boosted their price target on CeriBell from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Monday. William Blair started coverage on CeriBell in a research note on Tuesday, November 5th. They set an “outperform” rating on the stock. Finally, Canaccord Genuity Group initiated coverage on CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $30.00 target price for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $32.60.

CeriBell Trading Down 0.7 %

CeriBell stock opened at $30.04 on Monday. CeriBell has a twelve month low of $23.00 and a twelve month high of $32.53.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The business had revenue of $17.20 million during the quarter, compared to analysts’ expectations of $17.06 million. Analysts predict that CeriBell will post -2.46 earnings per share for the current fiscal year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.